Nuo Therapeutics In (GREY:NUOT)

Cytomedix, Inc., a biotechnology company, engages in the development, sale, and licensing of regenerative biological therapies for wound care, inflammation, and angiogenesis in the United States. The company provides the AutoloGel System, a device for the production of platelet rich plasma gel that is derived from the patient’s own blood. Its products include the AutoloGel System Centrifuge II, the AutoloGel wound dressing Kit, and AutoloGel reagents kit that are used for the treatment of exuding wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers, as well as for the management of mechanically or surgically debrided wounds. The company also focuses on developing CT-112, which is an anti-inflammatory peptide. Cytomedix, Inc. sells its products primarily to health care providers. The company was formerly known as Autologous Wound Therapy, Inc. and changed its name to Cytomedix, Inc. in 2000. Cytomedix, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Web site: http://www.cytomedix.com

Last updated September 29, 2011